 Quinolones
"Quinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
| Descriptor ID |
D015363
|
| MeSH Number(s) |
D03.633.100.810.835
|
| Concept/Terms |
Quinolones- Quinolones
- Quinolinones
- Ketoquinolines
- Oxoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Quinolones".
Below are MeSH descriptors whose meaning is more specific than "Quinolones".
This graph shows the total number of publications written about "Quinolones" by people in this website by year, and whether "Quinolones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 | | 1996 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 3 | 1 | 4 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2014 | 1 | 0 | 1 | | 2015 | 4 | 0 | 4 | | 2016 | 2 | 1 | 3 | | 2017 | 5 | 0 | 5 | | 2018 | 7 | 2 | 9 | | 2019 | 4 | 3 | 7 | | 2020 | 5 | 1 | 6 | | 2021 | 5 | 5 | 10 | | 2022 | 2 | 4 | 6 | | 2023 | 3 | 1 | 4 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. Am J Respir Crit Care Med. 2024 02 01; 209(3):299-306.
-
Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun; 14(6):1079-1087.
-
Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023 09 30; 402(10408):1171-1184.
-
Meltzer LJ, Gross JE. Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024 Jan; 23(1):132-136.
-
Taylor-Cousar JL, Shteinberg M, Cohen-Cymberknoh M, Jain R. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis. Clin Ther. 2023 03; 45(3):278-289.
-
Caverly LJ, Riquelme SA, Hisert KB. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation. Clin Chest Med. 2022 12; 43(4):647-665.
-
Jain R, Magaret A, Vu PT, VanDalfsen JM, Keller A, Wilson A, Putman MS, Mayer-Hamblett N, Esther CR, Taylor-Cousar JL. Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res. 2022 06; 9(1).
-
Gabel ME, Wang H, Gelfond D, Roach C, Rowe SM, Clancy JP, Sagel SD, Borowitz D. Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):42-47.
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. J Cyst Fibros. 2022 07; 21(4):637-643.
-
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022 03 01; 205(5):529-539.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|